Cas:1352925-68-8 tert-butyl 4-[(benzylamino)methyl]-4-hydroxypiperidine-1-carboxylate manufacturer & supplier

Chemical Name:tert-butyl 4-[(benzylamino)methyl]-4-hydroxypiperidine-1-carboxylate

CAS.NO:1352925-68-8

Synonyms:tert-butyl 4-[(benzylamino)methyl]-4-hydroxypiperidine-1-carboxylate

Molecular Formula:C₁₈H₂₈N₂O₃

Molecular Weight:320.42700

HS Code:2933399090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:61.80000

Exact Mass:320.21000

LogP:2.86700

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like tert-butyl 4-[(benzylamino)methyl]-4-hydroxypiperidine-1-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,tert-butyl 4-[(benzylamino)methyl]-4-hydroxypiperidine-1-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,tert-butyl 4-[(benzylamino)methyl]-4-hydroxypiperidine-1-carboxylate Use and application,tert-butyl 4-[(benzylamino)methyl]-4-hydroxypiperidine-1-carboxylate technical grade,usp/ep/jp grade.

Related News: At ASH, scientists from the Company and MSK presented new in vivo preclinical data demonstrating that FT819 exhibits durable tumor control and extended survival. tert-butyl 4-[(benzylamino)methyl]-4-hydroxypiperidine-1-carboxylate manufacturer In the TOP50 list of API export companies in 2017, the geographical clustering of advantageous companies is still obvious. For example, Huahai and Pluo in Zhejiang, CSPC of Hebei, Xinhua Pharmaceutical and Xinfa Pharmaceutical of Shandong rank well. Rank. tert-butyl 4-[(benzylamino)methyl]-4-hydroxypiperidine-1-carboxylate supplier The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy. tert-butyl 4-[(benzylamino)methyl]-4-hydroxypiperidine-1-carboxylate vendor At ASH, scientists from the Company and MSK presented new in vivo preclinical data demonstrating that FT819 exhibits durable tumor control and extended survival. tert-butyl 4-[(benzylamino)methyl]-4-hydroxypiperidine-1-carboxylate factory The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.